Copyright
©The Author(s) 2017.
World J Gastroenterol. Aug 21, 2017; 23(31): 5823-5828
Published online Aug 21, 2017. doi: 10.3748/wjg.v23.i31.5823
Published online Aug 21, 2017. doi: 10.3748/wjg.v23.i31.5823
Cases | Age (yr) | Sex | Daily dose (mg) | Duration (mo) | Type 4 collagen 7S (ng/mL) | Hepatic fibrosis | Portal hypertension |
1[1] | 81 | M | 400 | 48 | 12 | Bridging fibrosis | Esophageal varices |
Ascites | |||||||
2[3] | 76 | F | NA | 24 | NA | Bridging fibrosis | Ascites |
3[4] | 82 | M | 300 | 48 | 12 | Bridging fibrosis | NA |
4[4] | 73 | M | 300 | 23 | 11 | Bridging fibrosis | NA |
5[4] | 68 | F | 400 | 55 | 12 | Bridging fibrosis | NA |
Our case | 74 | F | 400 | 8 | 16 | Bridging fibrosis | Esophageal varices |
With septation | Ascites | ||||||
Splenomegaly |
- Citation: Honda S, Sawada K, Hasebe T, Nakajima S, Fujiya M, Okumura T. Tegafur-uracil-induced rapid development of advanced hepatic fibrosis. World J Gastroenterol 2017; 23(31): 5823-5828
- URL: https://www.wjgnet.com/1007-9327/full/v23/i31/5823.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i31.5823